Skip to main content

Information on COVID-19 for Healthcare Providers: Learn More

PMH Care Pathways: Progesterone Treatment and Cervical Length Screening

Progesterone Treatment and Cervical Length Screening

Prematurity remains the leading cause of neonatal morbidity and mortality. Two major risk factors for preterm birth are a history of previous spontaneous preterm birth and a short cervix on ultrasound screening.

In low-risk patients with an incidental finding of a short cervix noted at the time of anatomy ultrasound (16 to 20 weeks gestation), daily treatment with vaginal progesterone has been shown to reduce the risk of spontaneous preterm birth.

In patients with a previous history of spontaneous preterm birth, treatment with weekly intramuscular 17alpha hydroxyprogesterone (17P) has been shown to significantly reduce the risk of recurrence. In those with a singleton gestation who have a history of a spontaneous preterm birth and a current shortened cervix on ultrasound, placement of a cerclage reduces the risk of preterm birth.

The following outlines a management plan for the utilization of second trimester ultrasound to screen for a short cervix and progesterone therapy to reduce the incidence of preterm birth.

Please fill out the form to receive the PMH Pathway. Contact Paul Mahoney for any questions. 


CCNC is asking for this information to better understand who is using these resources and to further develop content to meet your needs. Your information will not be used unless you have indicated your interest in joining CCNC’s mailing list.